ABUS vs JNJ · P/E 5.4, rev $180.1M vs P/E 17, rev $49.37B
Arbutus Biopharma Corp (ABUS) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the ABUS and JNJ stock pages for the full models.
Not investment advice.